Modulating the activity of short arginine-tryptophan containing antibacterial peptides with N-terminal metallocenoyl groups

• H. Bauke Albada,
• Alina-Iulia Chiriac,
• Michaela Wenzel,
• Maya Penkova,
• Julia E. Bandow,
• Hans-Georg Sahl and
• Nils Metzler-Nolte

Beilstein J. Org. Chem. 2012, 8, 1753–1764, doi:10.3762/bjoc.8.200

• running dry [1]. For example, the number of methicillin-resistant Staphylococcus aureus (MRSA) infections in hospitals are still very high and new infectious agents like Acinetobacter baumannii are on the rise, both leading to increased numbers of mortality. In view of this, the discovery of host-defense

• in Table 2) The minimal inhibitory concentrations (MIC) were tested against Escherichia coli DSM 30083, Acinetobacter baumannii DSM 30007, Pseudomonas aeruginosa DSM 50071, Bacillus subtilis DSM 402, Staphylococcus aureus DSM 20231 (type strain), and Staphylococcus aureus ATCC 43300 (MRSA) in a

A macrolactonization approach to the total synthesis of the antimicrobial cyclic depsipeptide LI-F04a and diastereoisomeric analogues

• James R. Cochrane,
• Dong Hee Yoon,
• Christopher S. P. McErlean and
• Katrina A. Jolliffe

Beilstein J. Org. Chem. 2012, 8, 1344–1351, doi:10.3762/bjoc.8.154

• strains of Bacillus (Paenebacillus) and exhibit antifungal and antibacterial activity against a range of clinically relevant species, including Candida albicans, Cryptococcus neoformans, Staphylococcus aureus and Micrococcus luteus [1][2][3][4][5][6][7]. These compounds have a cyclic hexadepsipeptide core

Binaphthyl-anchored antibacterial tripeptide derivatives with hydrophobic C-terminal amino acid variations

• John B. Bremner,
• Paul A. Keller,
• Stephen G. Pyne,
• Mark J. Robertson,
• K. Sakthivel,
• Kittiya Somphol,
• Dean Baylis,
• Jonathan A. Coates,
• John Deadman,
• Dharshini Jeevarajah and
• David I. Rhodes

Beilstein J. Org. Chem. 2012, 8, 1265–1270, doi:10.3762/bjoc.8.142

• -terminal amino acid component, is described. Moderate to good activity was seen against Gram-positive bacteria in vitro. One cyclohexyl-substituted compound 2c was tested more widely and showed good potency (MIC values ranging from 2–4 μg/mL) against antibiotic-resistant strains of Staphylococcus aureus

• salts 2a–g were tested against the Gram-positive bacteria Staphylococcus aureus (ATCC 6538) and four clinical isolates of vancomycin-resistant (and sensitive) enterococci (VRE; Enterococcus faecium), and the results are shown in Table 1; some compounds were also tested against Staphylococcus epidermidis

• % pure. Determination of minimum inhibitory concentration (MIC) MIC studies (Table 1) were performed on Staphylococcus aureus wild type (ATCC 6538P), and Staphylococcus epidermidis (ATCC 12228) in Mueller–Hinton broth (Oxoid Ltd, England) supplemented with 50 mg/L CaCl2. As in [6], MIC determinations for

Partial thioamide scan on the lipopeptaibiotic trichogin GA IV. Effects on folding and bioactivity

• Marta De Zotti,
• Barbara Biondi,
• Cristina Peggion,
• Matteo De Poli,
• Haleh Fathi,
• Simona Oancea,
• Claudio Toniolo and
• Fernando Formaggio

Beilstein J. Org. Chem. 2012, 8, 1161–1171, doi:10.3762/bjoc.8.129

• bacterial strains. We found that [Leu11-OMe] trichogin GA IV is active on the Gram-positive bacteria Staphylococcus aureus and Streptococcus pyrogenes, whereas the spectrum of action of its three analogues is more restricted, as they are not active on the latter strain. The activities of the analogues on S

• activity assay was performed in a similar way to that described in reference [77]. The activity of peptides was tested against clinical isolates of bacteria and reference bacterial strains: Staphylococcus aureus American Type Culture Collection strains (ATCC) 25923, Streptococcus pyogenes ATCC 19615

Similarity analysis, synthesis, and bioassay of antibacterial cyclic peptidomimetics

• Workalemahu M. Berhanu,
• Mohamed A. Ibrahim,
• Girinath G. Pillai,
• Alexander A. Oliferenko,
• Levan Khelashvili,
• Farukh Jabeen,
• Bushra Mirza,
• Farzana Latif Ansari,
• Ihsan ul-Haq,
• Said A. El-Feky and
• Alan R. Katritzky

Beilstein J. Org. Chem. 2012, 8, 1146–1160, doi:10.3762/bjoc.8.128

• -, O-, C- and S-acylations. Results and Discussion Similarity analysis Our literature search identified the thirty three cyclic peptides and peptidomimetic structures given in Table 1. All the minimum inhibition constants (MIC) are pertinent to Staphylococcus aureus. These include (i) one 12-membered

• dataset of existing analogues. As abundant data can be found in the literature for Staphylococcus aureus, this was chosen as a reference for antibacterial activity. SciFinder Scholar was used to retrieve the structures of 33 cyclic peptides with reported antibacterial activity (Table 1). The minimum

Synthesis of szentiamide, a depsipeptide from entomopathogenic Xenorhabdus szentirmaii with activity against Plasmodium falciparum

• Friederike I. Nollmann,
• Andrea Dowling,
• Marcel Kaiser,
• Klaus Deckmann,
• Sabine Grösch,
• Richard ffrench-Constant and
• Helge B. Bode

Beilstein J. Org. Chem. 2012, 8, 528–533, doi:10.3762/bjoc.8.60

• different Gram-positive (Micrococcus luteus, Bacillus subtilis, Staphylococcus aureus) and Gram-negative (Escherichia coli, Pseudomonas aeroginosa) bacteria, as well as yeast (Candida albicans, Saccharomyces cerivisiae). However, consistent with the published data [12], no antibacterial or antifungal

Synthesis and characterization of new diiodocoumarin derivatives with promising antimicrobial activities

• Hany M. Mohamed,
• Ashraf H. F. Abd EL-Wahab,
• Ahmed M. EL-Agrody,
• Ahmed H. Bedair,
• Fathy A. Eid,
• Mostafa M. Khafagy and
• Kamal A. Abd-EL-Rehem

Beilstein J. Org. Chem. 2011, 7, 1688–1696, doi:10.3762/bjoc.7.199

• activity, better than the standard ampicillin, against two species of Gram-positive bacteria, Staphylococcus aureus (NCTC-7447), Bacillus cereus (ATCC-14579) and two Gram-negative bacteria, Escherichia coli (NCTC-10410) and Serratia marcescens (IMRU-70), while the same compounds showed moderate antifungal

• bacteria, namely Staphylococcus aureus (NCTC-7447), Bacillus cereus (ATCC-14579), and two Gram-negative bacteria, namely Escherichia coli (NCTC-10410), Serratia marcescens (IMRU-70); and against two species of fungi, namely Aspergillus fumigatus (MTCC-3008) and Candida albicans (MTCC-227). The tested

Scalable synthesis of (1-cyclopropyl)cyclopropylamine hydrochloride

• Sergei I. Kozhushkov,
• Alexander F. Khlebnikov,
• Rafael R. Kostikov,
• Dmitrii S. Yufit and
• Armin de Meijere

Beilstein J. Org. Chem. 2011, 7, 1003–1006, doi:10.3762/bjoc.7.113

• )cyclopropylamine (4) have been found to be useful variously for the treatment of hepatitis C [3][4], as pest control agents [5], as inhibitors of methicillin-resistant Staphylococcus aureus [5], as pesticides, insecticides and acaricides [7][8][9][10][11][12][13] and more. This amine has been prepared from

Synthesis, reactivity and biological activity of 5-alkoxymethyluracil analogues

• Lucie Brulikova and
• Jan Hlavac

Beilstein J. Org. Chem. 2011, 7, 678–698, doi:10.3762/bjoc.7.80

• tested for their antimicrobial activity against standard reference gram-positive and gram-negative bacterial strains such as Enterococcus faecalis CCM 4224, Staphylococcus aureus CCM 3953, Escherichia coli CCM 3954 and Pseudomonas aeruginosa CCM 3955 and against gram-positive and gram-negative bacteria

• obtained from clinical material of patients treated at the University Hospital in Olomouc (methicillin resistant Staphylococcus aureus - MRSA, Staphylococcus haemolyticus, Escherichia coli and Pseudomonas aeruginosa) with resistance to currently used fluoroquinolones. Only the octyl and nonyl derivatives

• 126h, 127h and 126i, 127i showed slight activity against Enterococcus faecalis CCM 4224, Staphylococcus aureus CCM 3953, Staphylococcus aureus (MRSA) and Staphylococcus haemolyticus. Conclusion This review was an attempt to summarize all available information on the synthesis and biological activity of